Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model
Molecules · 2024
DOI: 10.3390/molecules29081801 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Sena Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Pyrazoles, Transplantation, Homologous. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Bigelow Aerospace, American Cancer Society.
Abstract (Originalsprache)
Allogeneic hematopoietic cell transplantation (allo-HCT) is a highly effective, well-established treatment for patients with various hematologic malignancies and non-malignant diseases. The therapeutic benefits of allo-HCT are mediated by alloreactive T cells in donor grafts. However, there is a significant risk of graft-versus-host disease (GvHD), in which the donor T cells recognize recipient cells as foreign and attack healthy organs in addition to malignancies. We previously demonstrated that targeting JAK1/JAK2, mediators of interferon-gamma receptor (IFNGR) and IL-6 receptor signaling, in donor T cells using baricitinib and ruxolitinib results in a significant reduction in GvHD after allo-HCT. Furthermore, we showed that balanced inhibition of JAK1/JAK2 while sparing JAK3 is important for the optimal prevention of GvHD. Thus, we have generated novel JAK1/JAK2 inhibitors, termed WU derivatives, by modifying baricitinib. Our results show that WU derivatives have the potential to mitigate GvHD by upregulating regulatory T cells and immune reconstitution while reducing the frequencies of antigen-presenting cells (APCs) and CD80 expression on these APCs in our preclinical mouse model of allo-HCT. In addition, WU derivatives effectively downregulated CXCR3 and T-bet in primary murine T cells. In summary, we have generated novel JAK inhibitors that could serve as alternatives to baricitinib or ruxolitinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
ORCID-Profile: Sena Kim, Kidist Ashami, Jaebok Choi
Förderung
- NCI NIH HHS
- Bigelow Aerospace
- American Cancer Society
Zitieren
APA
Kim, S., Ruminski, P., Singh, M., Staser, K., Ashami, K., Ritchey, J., Lim, S., DiPersio, J. F., & Choi, J. (2024). Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model. Molecules. https://doi.org/10.3390/molecules29081801
Vancouver
Kim S, Ruminski P, Singh M, Staser K, Ashami K, Ritchey J, et al. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model. Molecules. 2024. doi:10.3390/molecules29081801
BibTeX
@article{Kim2024,
author = {Kim, Sena and Ruminski, Peter and Singh, Megh and Staser, Karl and Ashami, Kidist and Ritchey, Julie and Lim, Sora and DiPersio, John F and Choi, Jaebok},
title = {Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29081801}
}
EUVIMED